Today's Rundown Did Gilead's remdesivir flop a Chinese trial? Analysts beg to differ Ex-BARDA chief decries science taking back seat to politics, demands investigation into Trump administration One COVID-19 opportunity for pharma? A chance to bolster its reputation, Lilly CEO says Farzad Mostashari talks COVID recovery: 'It's not a light switch you turn on or off' AstraZeneca's fast-rising diabetes med Farxiga jumps into the COVID-19 fray Healthcare roundup: White House to release telehealth toolkit for states; Cuomo announces major contact tracing program Biopharma roundup: Gilead's remdesivir reportedly flops first COVID-19 trial; Could a crisis redeem pharma's rep? Half of physicians now using telehealth as COVID-19 changes practice operations Humana, NQF argue COVID-19 spotlights need for population health evolution Medtronic details COVID-19 impacts, with 60% drop in U.S. sales Scientists explore using CAR-T and other engineered immune cells to target COVID-19 COVID-19 drained 8% of market value from Big Pharma in Q1, but Gilead and Regeneron soared: report BCBSA to Congress: Bring back COBRA subsidies Sanofi CEO Hudson continues crusade for European pandemic muscle Icon to slash costs amid pandemic as 65% of its trial sites disrupted by COVID-19 Featured Story | | | Thursday, April 23, 2020 The World Health Organization accidentally revealed data from a study in China showing that the treatment neither improved patients’ condition nor tamped down on the amount of virus in their blood, Financial Times reported, calling the trial a “flop.” But was it really a flop? |
|
|---|
|
Top Stories Thursday, April 23, 2020 Ex-BARDA chief Rick Bright has launched an astonishing attack against “politics and cronyism” days after being kicked out of the agency leading the government’s push for a COVID-19 vaccine. Thursday, April 23, 2020 Pharma companies are a popular target for politicians, activists and critics in general. But with the world in dire need of COVID-19 drugs and vaccines, the industry has a "once in a generation" opportunity to revamp its reputation, Eli Lilly CEO Dave Ricks said Thursday. Thursday, April 23, 2020 FierceHealthcare spoke with Farzad Mostashari, M.D., a physician, entrepreneur, and former infectious disease epidemiologist, about the current health crisis, how it's impacting physician practices and the Trump administration's recent guidelines to reopen the country. Thursday, April 23, 2020 AstraZeneca's high-profile SGLT2 diabetes med Farxiga is looking at a bright future with big FDA decisions in heart failure and kidney disease right around the corner. Now, the British drugmaker is testing it as a potential coronavirus therapy, too. Thursday, April 23, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Thursday, April 23, 2020 Gilead Sciences' remdesivir reportedly flopped its first randomized trial to treat patients with severe COVID-19, but the drugmaker said the results were mischaracterized and that the trial ended earlier due to enrollment shortages. Thursday, April 23, 2020 Close to half of doctors are now using telehealth to treat patients as the COVID-19 pandemic changes how physicians deliver care. That's up from 18% in 2018. Find out how the current health crisis is changing practice patterns. Wednesday, April 22, 2020 The COVID-19 pandemic is putting a spotlight on why it’s critical for population-based models to consider the impacts of patients’ social needs, experts say. Thursday, April 23, 2020 As hospitals redirect resources toward COVID-19 and patients put off less-urgent medical procedures and trips to the doctor, Medtronic has seen serious impacts on its bottom line—including a 60% drop in weekly revenue from the U.S., where the medtech giant does most of its business. Thursday, April 23, 2020 CAR-T and TCR-T therapies that involve engineering a patient’s own immune cells with antigen-specific receptors have revolutionized blood cancer treatment. Now, scientists at Duke-NUS Medical School are exploring the possibility of turning the approach against COVID-19. Thursday, April 23, 2020 As the COVID-19 pandemic trounced markets around the world, most of biopharma's biggest companies saw their market capitalizations fall in the first quarter. There were a few exceptions, including Gilead, Regeneron and Roche, all of which gained on a combination of COVID-19 innovations and strength in their core businesses. Thursday, April 23, 2020 The Blue Cross Blue Shield Association has outlined its list of demands for Congress’ next package targeting the COVID-19 pandemic. Thursday, April 23, 2020 Sanofi CEO Paul Hudson would like to forge BARDA-like projects on Sanofi's home continent—but Europe has no BARDA equivalent to fund R&D or help scale up manufacturing. And he's calling on authorities there to set one up, stat. Thursday, April 23, 2020 As CROs report their first-quarter financials, Icon has issued some grim warnings about how much COVID-19 and the resultant lockdowns are hitting its business. |
